AR076617A1 - Compuestos de aminopirazol triazolotiadiazol inhibidores de la proteina quinasa c-met. - Google Patents

Compuestos de aminopirazol triazolotiadiazol inhibidores de la proteina quinasa c-met.

Info

Publication number
AR076617A1
AR076617A1 ARP100101868A ARP100101868A AR076617A1 AR 076617 A1 AR076617 A1 AR 076617A1 AR P100101868 A ARP100101868 A AR P100101868A AR P100101868 A ARP100101868 A AR P100101868A AR 076617 A1 AR076617 A1 AR 076617A1
Authority
AR
Argentina
Prior art keywords
compounds
triazolotiadiazol
aminopirazol
inhibitors
met
Prior art date
Application number
ARP100101868A
Other languages
English (en)
Inventor
David J Lauffer
Pan Li
Kira Mcginty
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42346870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR076617(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of AR076617A1 publication Critical patent/AR076617A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

También proporciona composiciones farmacéuticamente aceptables que comprenden compuestos de formula 1 y métodos para usar las composiciones en el tratamiento de trastornos proliferativos. Reivindicacion 1:Un compuesto que tiene la formula: (1), o una sal farmacéuticamente aceptable del mismo, donde R1 es alifático C1-3; R2 es hidrogeno, fluoro o metilo; R3 es hidrogeno, fluoro o metilo; cada R4 es, independientemente, hidrogeno o fluoro; y R5 es hidrogeno, cloro, ciclopropilo, o alifático C1-4 opcionalmente sustituido con 1-3 átomos de fluor.
ARP100101868A 2009-05-28 2010-05-28 Compuestos de aminopirazol triazolotiadiazol inhibidores de la proteina quinasa c-met. AR076617A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18178609P 2009-05-28 2009-05-28

Publications (1)

Publication Number Publication Date
AR076617A1 true AR076617A1 (es) 2011-06-22

Family

ID=42346870

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101868A AR076617A1 (es) 2009-05-28 2010-05-28 Compuestos de aminopirazol triazolotiadiazol inhibidores de la proteina quinasa c-met.

Country Status (26)

Country Link
EP (1) EP2435443B1 (es)
JP (1) JP5686796B2 (es)
KR (1) KR20120030110A (es)
CN (1) CN102459283B (es)
AR (1) AR076617A1 (es)
AU (1) AU2010254055B2 (es)
BR (1) BRPI1012037A2 (es)
CA (1) CA2762190A1 (es)
CL (1) CL2011002946A1 (es)
DK (1) DK2435443T3 (es)
ES (1) ES2433090T3 (es)
HK (1) HK1169105A1 (es)
HR (1) HRP20130986T1 (es)
IL (1) IL216581A (es)
MX (1) MX2011012521A (es)
NZ (1) NZ596616A (es)
PL (1) PL2435443T3 (es)
PT (1) PT2435443E (es)
RS (1) RS53011B (es)
RU (1) RU2552993C2 (es)
SG (1) SG176574A1 (es)
SI (1) SI2435443T1 (es)
TW (1) TWI491614B (es)
UA (1) UA106082C2 (es)
WO (1) WO2010138665A1 (es)
ZA (1) ZA201108655B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102448968A (zh) * 2009-05-28 2012-05-09 沃泰克斯药物股份有限公司 C-met蛋白激酶的取代的吡唑抑制剂
JP2013527195A (ja) * 2010-05-27 2013-06-27 バーテックス ファーマシューティカルズ インコーポレイテッド ｃ−Ｍｅｔプロテインキナーゼのアミノピラゾールトリアゾロチアジアゾールインヒビター
TR201113223A2 (tr) * 2011-12-29 2012-06-21 Koçak Farma İlaç Ve Ki̇mya Sanayi̇ A. Ş. Pemetrekset disodyum hazırlanmasına yönelik tek basamaklı işlem.
KR101373912B1 (ko) 2012-03-26 2014-03-13 중앙대학교 산학협력단 Ｓｈｐ－2의 활성을 특이적으로 저해하는 조성물 및 이의 제조방법
CN106924260B (zh) * 2015-12-31 2018-05-25 北京浦润奥生物科技有限责任公司 化合物在制备用于治疗脑胶质瘤的药物中的用途
CN109897054B (zh) * 2017-12-08 2021-12-10 中国药科大学 三唑并噻二唑类c-Met激酶抑制剂的制备方法及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
CN1863780A (zh) * 2002-08-14 2006-11-15 沃泰克斯药物股份有限公司 蛋白激酶抑制剂及其应用
US7122548B2 (en) * 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
JO2629B1 (en) * 2004-08-19 2012-06-24 افينتيس فارما سوتيكالز انك Branched carboxylic acid amides containing thienobirol, carboxylic acid amides containing pyrolithiazole, and the like as kinase inhibitors casein epsilon
EP1963329B1 (en) * 2005-11-30 2013-01-23 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
CN101360748B (zh) * 2005-11-30 2012-05-30 沃泰克斯药物股份有限公司 c-MET抑制剂及其应用
NL2000613C2 (nl) * 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
EA200971077A1 (ru) * 2007-05-21 2010-04-30 ЭсДжиЭкс ФАРМАСЬЮТИКАЛЗ, ИНК. Гетероциклические модуляторы киназы
CA2743000A1 (en) * 2008-11-19 2010-05-27 Vertex Pharmaceuticals Incorporated A triazolothiadiazole inhibitor of c-met protein kinase
CN102448968A (zh) * 2009-05-28 2012-05-09 沃泰克斯药物股份有限公司 C-met蛋白激酶的取代的吡唑抑制剂

Also Published As

Publication number Publication date
CN102459283B (zh) 2014-11-12
RU2552993C2 (ru) 2015-06-10
KR20120030110A (ko) 2012-03-27
CL2011002946A1 (es) 2012-07-27
ES2433090T3 (es) 2013-12-09
JP5686796B2 (ja) 2015-03-18
EP2435443B1 (en) 2013-07-31
IL216581A (en) 2014-02-27
JP2012528186A (ja) 2012-11-12
CA2762190A1 (en) 2010-12-02
UA106082C2 (uk) 2014-07-25
PL2435443T3 (pl) 2014-01-31
NZ596616A (en) 2013-05-31
AU2010254055A1 (en) 2011-12-15
HK1169105A1 (en) 2013-01-18
SG176574A1 (en) 2012-01-30
IL216581A0 (en) 2012-02-29
BRPI1012037A2 (pt) 2016-05-17
RU2011153613A (ru) 2013-07-10
TWI491614B (zh) 2015-07-11
SI2435443T1 (sl) 2013-12-31
EP2435443A1 (en) 2012-04-04
TW201100436A (en) 2011-01-01
WO2010138665A1 (en) 2010-12-02
HRP20130986T1 (hr) 2013-11-22
MX2011012521A (es) 2012-01-30
ZA201108655B (en) 2013-01-30
DK2435443T3 (da) 2013-10-28
RS53011B (en) 2014-04-30
CN102459283A (zh) 2012-05-16
AU2010254055B2 (en) 2016-01-14
PT2435443E (pt) 2013-10-31

Similar Documents

Publication Publication Date Title
CY1121360T1 (el) Αναστολεις dna-pk
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA200800760A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
EA201200669A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
PE20141597A1 (es) Triazolopiridinas sustituidas
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
AR080328A1 (es) Tienopirimidinas que contienen un grupo alquilo sustituido inhibidoras de quinasas mnk1 y/o mnk2, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de trastornos metabolicos tales como diabetes y obesidad, y trastornos hiperproliferativos, entre otros
EA201691484A1 (ru) Соли и твердая форма ингибитора btk
GT201100181A (es) "inhibidores de proteina cinasa"
CY1113386T1 (el) Αναστολεις πρωτεασωματος
EA201491356A1 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
BR112014003237A2 (pt) compostos de indazol, composições e métodos de uso
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201400358A1 (ru) Замещенные n-[1-циано-2-(фенил)этил]-2-азабицикло[2.2.1]гептан-3-карбоксамидные ингибиторы катепсина с
PE20151860A1 (es) Derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida y su uso como inhidores de la phd
AR076617A1 (es) Compuestos de aminopirazol triazolotiadiazol inhibidores de la proteina quinasa c-met.
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
MX2017004950A (es) Composiciones y metodos para tratar el insomnio.

Legal Events

Date Code Title Description
FB Suspension of granting procedure